Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound

Journal of Neuroimmunology

Volumn 80, Issue 1-2, 1997, Pages 143-148

  Patrini, Gabriela ^a   Sacerdote, Paola ^b   Fuzio, Domenica ^a   Manfredi, Barbara ^b   Parolaro, Daniela ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

CP 55,940; Natural killer cytotoxicity; Splenocyte proliferation; SR141716A

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; RECEPTOR SUBTYPE; RIMONABANT;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MALE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL;

ANIMALS; BEHAVIOR, ANIMAL; CANNABINOIDS; CYCLOHEXANOLS; CYTOTOXICITY, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SPLEEN;

EID: 0031469240     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00149-5     Document Type: Article

References (34)

1. Blanchard D.K., Newton C., Klein T.W., Stewart W.E. II, Friedman H. In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. Int. J. Immunopharmacol. 8:1996;819-824.
2. Cabral, G.A., Vasquez, R., 1991. Effects of marijuana on macrophage function In: Friedman, H. (Ed.), Drugs of Abuse, Immunity, and Immunodeficiency. Plenum Press, New York, pp. 93-105.
3. Cabral G.A., Pettit D.A., Fisher-Stenger K. Marijuana inhibition of cytotoxic T lymphocyte activity. Adv. Biosci. 86:1993;653-662.
4. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
5. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-77.
6. Edsall S.A., Knapp R.J., Vanderah T.W., Roeske W.R., Consroe P., Yamamura H.I. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. Neuroreport. 7:1996;593-596.
7. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
8. Kaminski N.E., Abood M.E., Kessler F.K., Martin B.R., Schatz A.R. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42:1992;736-742.
9. Kaminski, N.E., 1993. Evidence for a cannabinoid receptor in immunomodulation by cannabinoid compounds. In: Friedman, H. (Ed.), Drug of Abuse, Immunity, and AIDS. Plenum Press, New York, pp. 115-120.
10. Kaminski N.E., Koh W.S., Yang K.H., Lee M., Kessler F.K. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem. Pharmacol. 48:1994;1899-1908.
11. Kaminski N.E. Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem. Pharmacol. 52:1996;1133-1140.
12. Kawakami Y., Klein T.W., Newton C., Djeu J.Y., Dennert G., Specter S., Friedman H. Suppression by cannabinoids of a cloned cell line with natural killer cell activity. Proc. Soc. Exp. Biol. Med. 187:1988;355-359.
13. Kawakami Y., Klein T.W., Newton C.A., Djeu J.Y., Specter S., Friedman H. Suppression of delta-9-tetrahydrocannabinol of interleukin-2 induced lymphocyte proliferation and lymphokine-activated killer cell activity. Int. J. Immunopharm. 10:1988;485-488.
14. Kawakami Y., Klein T.W., Newton C.A., McCarthy C.A., Djeu J.Y., Dennert G., Specter S., Friedman H. Suppression by cannabinoids of cloned cell line with natural killer cell activity. Proc. Soc. Exp. Biol. Med. 187:1988;355-359.
15. Klein T.W., Kawakami Y., Newton C., Friedman H. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J. Toxicol. Environ. Health. 32:1991;465-477.
16. 9-tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc. Soc. Exp. Biol. Med. 209:1995;205-212.
17. Lynn A.B., Herkenham M. Localization of cannabinoid rceptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids. J. Pharamcol. Exp. Ther. 268:1994;1612-1623.
18. Manfredi B., Sacerdote P., Bianchi M., Veljic-Radulovic J., Panerai A.E. Evidence for an opioid inhibitory effect on T cell proliferation. J. Neuroimmunol. 44:1993;43-48.
19. Massi P., Patrini G., Rubino T., Fuzio D., Parolaro D. Changes in rat spleen cannabinoid receptors after chronic CP-55,940: An autoradiographic study. Pharmacol. Biochem. Behav. 56:1997;821-827.
20. Munro S., Thomas K.L., Abu-Shar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
21. Panerai A.E., Manfredi B., Granucci F., Sacerdote P. The beta-endorphin inhibition of mitogen-induced splenocytes proliferation is mediated by central and peripheral paracrine/autocrine effects of the opioid. J. Neuroimmunol. 58:1995;71-76.
22. 9-tetrahydrocannabinol in mouse spleen cells. a potential mechanism for cannabinoid-mediated immunosuppression. Life Sci. 51:1992;25-30.
23. Rubino T., Massi P., Patrini G., Venier I., Giagnoni G., Parolaro D. Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: An in situ hybridization study. Neuroreport. 5:1994;2493-2496.
24. Rubino T., Patrini G., Parenti M., Massi P., Parolaro D. Chronic treatment with a syntetic cannabinoid CP-55,940 alters G-protein expression in rat central nervous system. Mol. Brain Res. 44:1997;191-197.
25. Sacerdote P., Manfredi B., Bianchi M., Panerai A.E. Intermittent but not continuous inescapable foot-shock stress affects immune responses and immunocyte beta-endorphin concentrations in the rat. Brain Behav. Immun. 8:1994;251-260.
26. 9-tetrahidrocannabinol. Int. J. Immunopharm. 8:1986;741-745.
27. Specter S., Lancz G., Hazelden J. Marijuana and Immunity: Tetrahydrocannabinol mediated inhibition of lymphocyte blastogenesis. Int. J. Immunopharm. 12:1990;261-267.
28. Specter, S., Lancz, G., 1991. Effects of marijuana on human natural killer cell activity. In: Friedman, H. (Ed.), Drugs of Abuse, Immunity, and Immunodeficiency. Plenum Press, New York, pp. 47-56.
29. Specter S., Lancz G., Goodfellow D. Suppression of human macrophage function in vitro by delta-9-tetrahydrocannabinol. J. Leukocyte Biol. 50:1991;423-426.
30. Specter S., Cabral G. Cannabinoids, immunity and resistance to infection. J. Neuroimmunol. 69:1996;15-23.
31. Tang J., Lancz G., Specter S., Bullock H. Marijuana and immunity: Tetrahydrocannabinol-mediated inhibition of growth and phagocytic activity of the murine macrophage cell line, P388D1. Int. J. Immunopharm. 14:1992;253-262.
32. Watzl, B., Scuderi, P., Watson, R.R., 1991. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. In: Friedman, H. (Ed.), Drugs of Abuse, Immunity, and Immunodeficiency. Plenum Press, New York, pp. 63-70.
33. Zhu W., Igarashi T., Qi Z.T., Newton C., Widen R.E., Friedman H., Klein T.W. Delta-9-tetrahydrocannabinol (THC) decreases the number of high and intermediate affinity IL-2 receptors of the IL-2 dependent cell line NKB61A2. Int. J. Immunopharm. 15:1993;401-408.
34. 9-tetrahydrocannabinol (THC) causes the variable expression of IL-2 receptor subunits. J. Pharmacol. Exp. Ther. 274:1995;1001-1007.